Publication: Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Kesselheim, Aaron S., Carolyn L. Treasure, and Steven Joffe. 2017. “Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.” PLoS Medicine 14 (1): e1002190. doi:10.1371/journal.pmed.1002190. http://dx.doi.org/10.1371/journal.pmed.1002190.
Research Data
Abstract
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.
Description
Other Available Sources
Keywords
Medicine and Health Sciences, Pharmacology, Drug Research and Development, Oncology, Biology and Life Sciences, Genetics, Mutation, Point Mutation, Deletion Mutation, Cancers and Neoplasms, Lung and Intrathoracic Tumors, Non-Small Cell Lung Cancer, Pharmaceutics, Drug Therapy, Drug Screening, Clinical Genetics, Genetic Diseases, Autosomal Recessive Diseases, Cystic Fibrosis, Developmental Biology, Fibrosis, Pulmonology
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service